P63_MOUSE
ID P63_MOUSE Reviewed; 680 AA.
AC O88898; O88897; O88899; O89097; Q8C826; Q9QWY9; Q9QWZ0;
DT 04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1998, sequence version 1.
DT 03-AUG-2022, entry version 197.
DE RecName: Full=Tumor protein 63;
DE Short=p63;
DE AltName: Full=Transformation-related protein 63;
DE Short=TP63;
DE AltName: Full=Tumor protein p73-like;
DE Short=p73L;
GN Name=Tp63; Synonyms=P63, P73l, Tp73l, Trp63;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Mus; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), AND TISSUE
RP SPECIFICITY.
RX PubMed=9774969; DOI=10.1016/s1097-2765(00)80275-0;
RA Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Doetsch V.,
RA Andrews N.C., Caput D., McKeon F.;
RT "p63, a p53 homolog at 3q27-29, encodes multiple products with
RT transactivating, death-inducing, and dominant-negative activities.";
RL Mol. Cell 2:305-316(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC TISSUE=Thymus;
RX PubMed=9703973; DOI=10.1006/bbrc.1998.9013;
RA Senoo M., Seki N., Ohira M., Sugano S., Watanabe M., Tachibana M.,
RA Tanaka T., Shinkai Y., Kato H.;
RT "A second p53-related protein, p73L, with high homology to p73.";
RL Biochem. Biophys. Res. Commun. 248:603-607(1998).
RN [3]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA Kui J.S., Wang J.H., Zhang M.Q., Mills A.A.;
RL Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-376 (ISOFORMS 2 AND 4).
RC STRAIN=C57BL/6J; TISSUE=Head;
RX PubMed=16141072; DOI=10.1126/science.1112014;
RA Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT "The transcriptional landscape of the mammalian genome.";
RL Science 309:1559-1563(2005).
RN [5]
RP FUNCTION IN EPITHELIAL MORPHOGENESIS.
RX PubMed=10227293; DOI=10.1038/19531;
RA Mills A.A., Zheng B., Wang X.-J., Vogel H., Roop D.R., Bradley A.;
RT "p63 is a p53 homologue required for limb and epidermal morphogenesis.";
RL Nature 398:708-713(1999).
RN [6]
RP FUNCTION IN EPITHELIAL MORPHOGENESIS.
RX PubMed=10227294; DOI=10.1038/19539;
RA Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T.,
RA Tabin C., Sharpe A., Caput D., Crum C., McKeon F.;
RT "p63 is essential for regenerative proliferation in limb, craniofacial and
RT epithelial development.";
RL Nature 398:714-718(1999).
RN [7]
RP FUNCTION IN TP53 DEPENDENT APOPTOSIS, AND INDUCTION.
RX PubMed=11932750; DOI=10.1038/416560a;
RA Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F.,
RA Jacks T.;
RT "p63 and p73 are required for p53-dependent apoptosis in response to DNA
RT damage.";
RL Nature 416:560-564(2002).
RN [8]
RP FUNCTION IN EPITHELIAL MORPHOGENESIS, SUBCELLULAR LOCATION, AND
RP DEVELOPMENTAL STAGE.
RX PubMed=14729569; DOI=10.1101/gad.1165104;
RA Koster M.I., Kim S., Mills A.A., DeMayo F.J., Roop D.R.;
RT "p63 is the molecular switch for initiation of an epithelial stratification
RT program.";
RL Genes Dev. 18:126-131(2004).
RN [9]
RP UBIQUITINATION, INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-543.
RX PubMed=18806757; DOI=10.1038/cdd.2008.134;
RA Li Y., Zhou Z., Chen C.;
RT "WW domain-containing E3 ubiquitin protein ligase 1 targets p63
RT transcription factor for ubiquitin-mediated proteasomal degradation and
RT regulates apoptosis.";
RL Cell Death Differ. 15:1941-1951(2008).
RN [10]
RP FUNCTION IN RIPK4 TRANSACTIVATION.
RX PubMed=22197488; DOI=10.1016/j.ajhg.2011.11.013;
RA Mitchell K., O'Sullivan J., Missero C., Blair E., Richardson R.,
RA Anderson B., Antonini D., Murray J.C., Shanske A.L., Schutte B.C.,
RA Romano R.A., Sinha S., Bhaskar S.S., Black G.C., Dixon J., Dixon M.J.;
RT "Exome sequence identifies RIPK4 as the Bartsocas-Papas syndrome locus.";
RL Am. J. Hum. Genet. 90:69-75(2012).
RN [11]
RP DEVELOPMENTAL STAGE.
RX PubMed=32758484; DOI=10.1016/j.ydbio.2020.07.016;
RA Simonson L., Vold S., Mowers C., Massey R.J., Ong I.M., Longley B.J.,
RA Chang H.;
RT "Keratin 13 deficiency causes white sponge nevus in mice.";
RL Dev. Biol. 468:146-153(2020).
CC -!- FUNCTION: Acts as a sequence specific DNA binding transcriptional
CC activator or repressor. The isoforms contain a varying set of
CC transactivation and auto-regulating transactivation inhibiting domains
CC thus showing an isoform specific activity. May be required in
CC conjunction with TP73/p73 for initiation of p53/TP53 dependent
CC apoptosis in response to genotoxic insults and the presence of
CC activated oncogenes. Involved in Notch signaling by probably inducing
CC JAG1 and JAG2. Activates transcription of the p21 promoter (By
CC similarity). Activates RIPK4 transcription. Plays a role in the
CC regulation of epithelial morphogenesis. The ratio of DeltaN-type and
CC TA*-type isoforms may govern the maintenance of epithelial stem cell
CC compartments and regulate the initiation of epithelial stratification
CC from the undifferentiated embryonal ectoderm. Required for limb
CC formation from the apical ectodermal ridge. {ECO:0000250,
CC ECO:0000269|PubMed:10227293, ECO:0000269|PubMed:10227294,
CC ECO:0000269|PubMed:11932750, ECO:0000269|PubMed:14729569,
CC ECO:0000269|PubMed:22197488}.
CC -!- COFACTOR:
CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC -!- SUBUNIT: Binds DNA as a homotetramer. Isoform composition of the
CC tetramer may determine transactivation activity. Interacts with HIPK2.
CC Interacts with SSRP1, leading to stimulate coactivator activity.
CC Interacts with PDS5A. Interacts (via activation domain) with NOC2L (By
CC similarity). Interacts with WWP1. {ECO:0000250,
CC ECO:0000269|PubMed:18806757}.
CC -!- INTERACTION:
CC O88898; Q9ESJ1: Cables1; NbExp=2; IntAct=EBI-2338025, EBI-604411;
CC O88898; O88898: Tp63; NbExp=2; IntAct=EBI-2338025, EBI-2338025;
CC O88898; P04637: TP53; Xeno; NbExp=2; IntAct=EBI-2338025, EBI-366083;
CC O88898-1; O88898-1: Tp63; NbExp=19; IntAct=EBI-3863990, EBI-3863990;
CC O88898-2; O88898-2: Tp63; NbExp=2; IntAct=EBI-2338228, EBI-2338228;
CC O88898-2; Q92831: KAT2B; Xeno; NbExp=3; IntAct=EBI-2338228, EBI-477430;
CC O88898-5; O88898-5: Tp63; NbExp=5; IntAct=EBI-2338240, EBI-2338240;
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14729569}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=6;
CC Name=1; Synonyms=TA*-alpha, TA*p63alpha;
CC IsoId=O88898-1; Sequence=Displayed;
CC Name=2; Synonyms=DeltaN-alpha;
CC IsoId=O88898-2; Sequence=VSP_012471;
CC Name=3; Synonyms=TA*-beta, TA*p63beta;
CC IsoId=O88898-3; Sequence=VSP_012474;
CC Name=4; Synonyms=DeltaN-beta;
CC IsoId=O88898-4; Sequence=VSP_012471, VSP_012474;
CC Name=5; Synonyms=TA*-gamma, TA*p63gamma;
CC IsoId=O88898-5; Sequence=VSP_012472, VSP_012473;
CC Name=6; Synonyms=DeltaN-gamma;
CC IsoId=O88898-6; Sequence=VSP_012471, VSP_012472, VSP_012473;
CC -!- TISSUE SPECIFICITY: Widely expressed, notably in thymus, prostate,
CC placenta and skeletal muscle, although the precise isoform varies
CC according to tissue type. Progenitor cell layers of skin, breast and
CC prostate express high levels of DeltaN-type isoforms.
CC {ECO:0000269|PubMed:9774969}.
CC -!- DEVELOPMENTAL STAGE: Expressed in the basal layer and a small number of
CC cells in the spinous layer of the tongue at P20.
CC {ECO:0000269|PubMed:14729569, ECO:0000269|PubMed:32758484}.
CC -!- DEVELOPMENTAL STAGE: [Isoform 1]: Expressed in the epidermis from 7.5
CC dpc, prior to onset of epithelial stratification.
CC {ECO:0000269|PubMed:14729569}.
CC -!- DEVELOPMENTAL STAGE: [Isoform 2]: Expressed in the epidermis from 9.5
CC dpc, after the onset of epithelial stratification but prior to terminal
CC differentiation. {ECO:0000269|PubMed:14729569}.
CC -!- DEVELOPMENTAL STAGE: [Isoform 3]: Expressed in the epidermis from 7.5
CC dpc, prior to onset of epithelial stratification.
CC {ECO:0000269|PubMed:14729569}.
CC -!- DEVELOPMENTAL STAGE: [Isoform 4]: Expressed in the epidermis from 9.5
CC dpc, after the onset of epithelial stratification but prior to terminal
CC differentiation. {ECO:0000269|PubMed:14729569}.
CC -!- DEVELOPMENTAL STAGE: [Isoform 5]: Expressed in the epidermis from 7.5
CC dpc, prior to onset of epithelial stratification.
CC {ECO:0000269|PubMed:14729569}.
CC -!- DEVELOPMENTAL STAGE: [Isoform 6]: Expressed in the epidermis from 9.5
CC dpc, after the onset of epithelial stratification but prior to terminal
CC differentiation. {ECO:0000269|PubMed:14729569}.
CC -!- INDUCTION: Induced by DNA damaging agents.
CC {ECO:0000269|PubMed:11932750}.
CC -!- DOMAIN: The transactivation inhibitory domain (TID) can interact with,
CC and inhibit the activity of the N-terminal transcriptional activation
CC domain of TA*-type isoforms. {ECO:0000250}.
CC -!- PTM: May be sumoylated. {ECO:0000250}.
CC -!- PTM: Ubiquitinated. Polyubiquitination involves WWP1 and leads to
CC proteasomal degradation of this protein. {ECO:0000269|PubMed:18806757}.
CC -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage.
CC {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing of isoform
CC 1. {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC 2. {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform
CC 1. {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative splicing of isoform
CC 2. {ECO:0000305}.
CC -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=BAC33397.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF075434; AAC62639.1; -; mRNA.
DR EMBL; AF075435; AAC62640.1; -; mRNA.
DR EMBL; AF075436; AAC62641.1; -; mRNA.
DR EMBL; AF075437; AAC62642.1; -; mRNA.
DR EMBL; AF075438; AAC62643.1; -; mRNA.
DR EMBL; AF075439; AAC62644.1; -; mRNA.
DR EMBL; AB010152; BAA32432.1; -; mRNA.
DR EMBL; AF533892; AAP87982.1; -; Genomic_DNA.
DR EMBL; AF533892; AAP87985.1; -; Genomic_DNA.
DR EMBL; AF533892; AAP87983.1; -; Genomic_DNA.
DR EMBL; AF533892; AAP87984.1; -; Genomic_DNA.
DR EMBL; AF533892; AAP87986.1; -; Genomic_DNA.
DR EMBL; AF533892; AAP87987.1; -; Genomic_DNA.
DR EMBL; AK048623; BAC33397.1; ALT_SEQ; mRNA.
DR CCDS; CCDS28085.1; -. [O88898-2]
DR CCDS; CCDS49808.1; -. [O88898-5]
DR CCDS; CCDS49809.1; -. [O88898-1]
DR CCDS; CCDS49810.1; -. [O88898-3]
DR RefSeq; NP_001120731.1; NM_001127259.1. [O88898-1]
DR RefSeq; NP_001120732.1; NM_001127260.1. [O88898-3]
DR RefSeq; NP_001120733.1; NM_001127261.1. [O88898-5]
DR RefSeq; NP_001120734.1; NM_001127262.1. [O88898-4]
DR RefSeq; NP_001120736.1; NM_001127264.1.
DR RefSeq; NP_001120737.1; NM_001127265.1. [O88898-6]
DR RefSeq; NP_035771.1; NM_011641.2. [O88898-2]
DR PDB; 5N2O; NMR; -; A=545-609.
DR PDBsum; 5N2O; -.
DR AlphaFoldDB; O88898; -.
DR BMRB; O88898; -.
DR SMR; O88898; -.
DR BioGRID; 204325; 8.
DR ELM; O88898; -.
DR IntAct; O88898; 7.
DR MINT; O88898; -.
DR STRING; 10090.ENSMUSP00000110965; -.
DR iPTMnet; O88898; -.
DR PhosphoSitePlus; O88898; -.
DR PaxDb; O88898; -.
DR PRIDE; O88898; -.
DR Antibodypedia; 1750; 1024 antibodies from 50 providers.
DR DNASU; 22061; -.
DR Ensembl; ENSMUST00000040231; ENSMUSP00000038117; ENSMUSG00000022510. [O88898-2]
DR Ensembl; ENSMUST00000065523; ENSMUSP00000067005; ENSMUSG00000022510. [O88898-3]
DR Ensembl; ENSMUST00000115308; ENSMUSP00000110963; ENSMUSG00000022510. [O88898-5]
DR Ensembl; ENSMUST00000115310; ENSMUSP00000110965; ENSMUSG00000022510. [O88898-1]
DR GeneID; 22061; -.
DR KEGG; mmu:22061; -.
DR UCSC; uc007yuo.2; mouse. [O88898-5]
DR UCSC; uc007yup.2; mouse. [O88898-1]
DR UCSC; uc007yuq.2; mouse. [O88898-3]
DR UCSC; uc007yut.2; mouse. [O88898-6]
DR UCSC; uc007yuu.2; mouse. [O88898-2]
DR UCSC; uc007yuv.2; mouse. [O88898-4]
DR CTD; 22061; -.
DR MGI; MGI:1330810; Trp63.
DR VEuPathDB; HostDB:ENSMUSG00000022510; -.
DR eggNOG; ENOG502QQ48; Eukaryota.
DR GeneTree; ENSGT00950000183153; -.
DR HOGENOM; CLU_019621_1_0_1; -.
DR InParanoid; O88898; -.
DR OMA; IRMQDSE; -.
DR PhylomeDB; O88898; -.
DR TreeFam; TF106101; -.
DR Reactome; R-MMU-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR BioGRID-ORCS; 22061; 1 hit in 73 CRISPR screens.
DR ChiTaRS; Trp63; mouse.
DR PRO; PR:O88898; -.
DR Proteomes; UP000000589; Chromosome 16.
DR RNAct; O88898; protein.
DR Bgee; ENSMUSG00000022510; Expressed in hair follicle and 162 other tissues.
DR ExpressionAtlas; O88898; baseline and differential.
DR Genevisible; O88898; MM.
DR GO; GO:0000785; C:chromatin; ISO:MGI.
DR GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR GO; GO:0030425; C:dendrite; ISO:MGI.
DR GO; GO:0043005; C:neuron projection; ISO:MGI.
DR GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR GO; GO:0005634; C:nucleus; IDA:MGI.
DR GO; GO:0032991; C:protein-containing complex; ISO:MGI.
DR GO; GO:0005791; C:rough endoplasmic reticulum; ISO:MGI.
DR GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR GO; GO:0003684; F:damaged DNA binding; IDA:MGI.
DR GO; GO:0003677; F:DNA binding; IDA:MGI.
DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:MGI.
DR GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:MGI.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR GO; GO:0003690; F:double-stranded DNA binding; ISO:MGI.
DR GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR GO; GO:0097371; F:MDM2/MDM4 family protein binding; ISO:MGI.
DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR GO; GO:0002039; F:p53 binding; ISO:MGI.
DR GO; GO:0019904; F:protein domain specific binding; ISO:MGI.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:MGI.
DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:MGI.
DR GO; GO:0050699; F:WW domain binding; ISO:MGI.
DR GO; GO:0048646; P:anatomical structure formation involved in morphogenesis; IMP:MGI.
DR GO; GO:0009887; P:animal organ morphogenesis; IMP:MGI.
DR GO; GO:0006915; P:apoptotic process; TAS:MGI.
DR GO; GO:0006974; P:cellular response to DNA damage stimulus; ISO:MGI.
DR GO; GO:0090398; P:cellular senescence; IMP:MGI.
DR GO; GO:0006338; P:chromatin remodeling; IMP:MGI.
DR GO; GO:0060197; P:cloacal septation; IMP:MGI.
DR GO; GO:1904888; P:cranial skeletal system development; IMP:MGI.
DR GO; GO:0007499; P:ectoderm and mesoderm interaction; IMP:MGI.
DR GO; GO:0035115; P:embryonic forelimb morphogenesis; IMP:MGI.
DR GO; GO:0035116; P:embryonic hindlimb morphogenesis; IMP:MGI.
DR GO; GO:0030326; P:embryonic limb morphogenesis; IMP:MGI.
DR GO; GO:0009913; P:epidermal cell differentiation; IMP:MGI.
DR GO; GO:0010481; P:epidermal cell division; IMP:MGI.
DR GO; GO:0008544; P:epidermis development; IMP:MGI.
DR GO; GO:0002064; P:epithelial cell development; IMP:MGI.
DR GO; GO:0030855; P:epithelial cell differentiation; IMP:MGI.
DR GO; GO:0001736; P:establishment of planar polarity; IDA:MGI.
DR GO; GO:0061436; P:establishment of skin barrier; IMP:UniProtKB.
DR GO; GO:0048807; P:female genitalia morphogenesis; IMP:MGI.
DR GO; GO:0001942; P:hair follicle development; IMP:MGI.
DR GO; GO:0031069; P:hair follicle morphogenesis; IMP:MGI.
DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:MGI.
DR GO; GO:0030216; P:keratinocyte differentiation; IDA:MGI.
DR GO; GO:0043616; P:keratinocyte proliferation; IGI:MGI.
DR GO; GO:0001738; P:morphogenesis of a polarized epithelium; IMP:MGI.
DR GO; GO:0010259; P:multicellular organism aging; IMP:MGI.
DR GO; GO:2000773; P:negative regulation of cellular senescence; ISO:MGI.
DR GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IMP:CAFA.
DR GO; GO:0045617; P:negative regulation of keratinocyte differentiation; IMP:MGI.
DR GO; GO:2000381; P:negative regulation of mesoderm development; IMP:MGI.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:MGI.
DR GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISO:MGI.
DR GO; GO:0051402; P:neuron apoptotic process; IMP:MGI.
DR GO; GO:0007219; P:Notch signaling pathway; IMP:MGI.
DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR GO; GO:0007389; P:pattern specification process; IMP:MGI.
DR GO; GO:0030859; P:polarized epithelial cell differentiation; IMP:MGI.
DR GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IDA:MGI.
DR GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; ISO:MGI.
DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISO:MGI.
DR GO; GO:2000271; P:positive regulation of fibroblast apoptotic process; ISO:MGI.
DR GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IGI:MGI.
DR GO; GO:0045747; P:positive regulation of Notch signaling pathway; IMP:MGI.
DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISO:MGI.
DR GO; GO:1904674; P:positive regulation of somatic stem cell population maintenance; IMP:CAFA.
DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IGI:MGI.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:MGI.
DR GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISO:MGI.
DR GO; GO:0036342; P:post-anal tail morphogenesis; IMP:MGI.
DR GO; GO:0030850; P:prostate gland development; IMP:MGI.
DR GO; GO:0060513; P:prostatic bud formation; IMP:MGI.
DR GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR GO; GO:0009954; P:proximal/distal pattern formation; IMP:MGI.
DR GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:MGI.
DR GO; GO:0010482; P:regulation of epidermal cell division; IMP:UniProtKB.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR GO; GO:0001501; P:skeletal system development; IMP:MGI.
DR GO; GO:0098773; P:skin epidermis development; IMP:MGI.
DR GO; GO:0043589; P:skin morphogenesis; IMP:MGI.
DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; IMP:MGI.
DR GO; GO:0048863; P:stem cell differentiation; IMP:MGI.
DR GO; GO:0072089; P:stem cell proliferation; IMP:MGI.
DR GO; GO:0048485; P:sympathetic nervous system development; IMP:MGI.
DR GO; GO:0006366; P:transcription by RNA polymerase II; IDA:MGI.
DR CDD; cd08367; P53; 1.
DR CDD; cd09572; SAM_tumor-p63; 1.
DR Gene3D; 1.10.150.50; -; 1.
DR Gene3D; 2.60.40.720; -; 1.
DR Gene3D; 4.10.170.10; -; 1.
DR InterPro; IPR008967; p53-like_TF_DNA-bd.
DR InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR InterPro; IPR011615; p53_DNA-bd.
DR InterPro; IPR036674; p53_tetramer_sf.
DR InterPro; IPR010991; p53_tetrameristn.
DR InterPro; IPR002117; p53_tumour_suppressor.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR013761; SAM/pointed_sf.
DR InterPro; IPR032645; Tp63.
DR InterPro; IPR037611; Tumor-p63_SAM.
DR PANTHER; PTHR11447; PTHR11447; 1.
DR PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR Pfam; PF00870; P53; 1.
DR Pfam; PF07710; P53_tetramer; 1.
DR Pfam; PF07647; SAM_2; 1.
DR PRINTS; PR00386; P53SUPPRESSR.
DR SMART; SM00454; SAM; 1.
DR SUPFAM; SSF47719; SSF47719; 1.
DR SUPFAM; SSF47769; SSF47769; 1.
DR SUPFAM; SSF49417; SSF49417; 1.
DR PROSITE; PS00348; P53; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Activator; Alternative promoter usage; Alternative splicing;
KW Apoptosis; Developmental protein; DNA-binding; Isopeptide bond;
KW Metal-binding; Notch signaling pathway; Nucleus; Reference proteome;
KW Transcription; Transcription regulation; Ubl conjugation; Zinc.
FT CHAIN 1..680
FT /note="Tumor protein 63"
FT /id="PRO_0000185730"
FT DOMAIN 541..607
FT /note="SAM"
FT DNA_BIND 170..362
FT /evidence="ECO:0000250"
FT REGION 1..107
FT /note="Transcription activation"
FT /evidence="ECO:0000250"
FT REGION 123..171
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 351..393
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 352..388
FT /note="Interaction with HIPK2"
FT /evidence="ECO:0000250"
FT REGION 394..443
FT /note="Oligomerization"
FT /evidence="ECO:0000250"
FT REGION 436..472
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 610..680
FT /note="Transactivation inhibition"
FT /evidence="ECO:0000250"
FT COMPBIAS 123..166
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 364..389
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT BINDING 244
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /evidence="ECO:0000250"
FT BINDING 247
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /evidence="ECO:0000250"
FT BINDING 308
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /evidence="ECO:0000250"
FT BINDING 312
FT /ligand="Zn(2+)"
FT /ligand_id="ChEBI:CHEBI:29105"
FT /evidence="ECO:0000250"
FT CROSSLNK 676
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO)"
FT /evidence="ECO:0000250"
FT VAR_SEQ 1..108
FT /note="MNFETSRCATLQYCPDPYIQRFIETPAHFSWKESYYRSAMSQSTQTSEFLSP
FT EVFQHIWDFLEQPICSVQPIELNFVDEPSENGATNKIEISMDCIRMQDSDLSDPMW ->
FT MLYLENNAQTQFSE (in isoform 2, isoform 4 and isoform 6)"
FT /evidence="ECO:0000303|PubMed:16141072,
FT ECO:0000303|PubMed:9703973, ECO:0000303|PubMed:9774969"
FT /id="VSP_012471"
FT VAR_SEQ 373..377
FT /note="GTKRP -> A (in isoform 5 and isoform 6)"
FT /evidence="ECO:0000303|PubMed:9774969"
FT /id="VSP_012472"
FT VAR_SEQ 450..680
FT /note="QTSMQSQSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTMPEGMGA
FT NIPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSS
FT CLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHDFSSPPHLLRT
FT PSGASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDSRRNKQQRIKEE
FT GE -> HLLSACFRNELVEPRGEAPTQSDVFFRHSNPPNHSVYP (in isoform 5
FT and isoform 6)"
FT /evidence="ECO:0000303|PubMed:9774969"
FT /id="VSP_012473"
FT VAR_SEQ 551..680
FT /note="SFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGIL
FT DHRQLHDFSSPPHLLRTPSGASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDF
FT NFDMDSRRNKQQRIKEEGE -> RIWQV (in isoform 3 and isoform 4)"
FT /evidence="ECO:0000303|PubMed:16141072,
FT ECO:0000303|PubMed:9774969"
FT /id="VSP_012474"
FT MUTAGEN 543
FT /note="Y->F: Abolishes interaction with WWP1."
FT /evidence="ECO:0000269|PubMed:18806757"
FT HELIX 549..556
FT /evidence="ECO:0007829|PDB:5N2O"
FT HELIX 560..568
FT /evidence="ECO:0007829|PDB:5N2O"
FT HELIX 573..576
FT /evidence="ECO:0007829|PDB:5N2O"
FT HELIX 581..586
FT /evidence="ECO:0007829|PDB:5N2O"
FT HELIX 591..607
FT /evidence="ECO:0007829|PDB:5N2O"
SQ SEQUENCE 680 AA; 76789 MW; 8DFF0284F247C68A CRC64;
MNFETSRCAT LQYCPDPYIQ RFIETPAHFS WKESYYRSAM SQSTQTSEFL SPEVFQHIWD
FLEQPICSVQ PIELNFVDEP SENGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
KQQVSDSAKN GDGTKRPFRQ NTHGIQMTSI KKRRSPDDEL LYLPVRGRET YEMLLKIKES
LELMQYLPQH TIETYRQQQQ QQHQHLLQKQ TSMQSQSSYG NSSPPLNKMN SMNKLPSVSQ
LINPQQRNAL TPTTMPEGMG ANIPMMGTHM PMAGDMNGLS PTQALPPPLS MPSTSHCTPP
PPYPTDCSIV SFLARLGCSS CLDYFTTQGL TTIYQIEHYS MDDLASLKIP EQFRHAIWKG
ILDHRQLHDF SSPPHLLRTP SGASTVSVGS SETRGERVID AVRFTLRQTI SFPPRDEWND
FNFDMDSRRN KQQRIKEEGE
